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Abstract
: Deubiquitylating enzymes (DUBs) can hydrolyze a peptide, amide, ester or thiolester bond at the
C-terminus of UBIQ (ubiquitin), including the post-translationally formed branched peptide bonds
in mono- or multi-ubiquitylated conjugates. DUBs thus have the potential to regulate any UBIQ-
mediated cellular process, the two best characterized being proteolysis and protein trafficking.
Mammals contain some 80–90 DUBs in five different subfamilies, only a handful of which have been
characterized with respect to the proteins that they interact with and deubiquitylate. Several other
DUBs have been implicated in various disease processes in which they are changed by mutation,
have altered expression levels, and/or form part of regulatory complexes. Specific examples of
DUB involvement in various diseases are presented. While no specific drugs targeting DUBs have
yet been described, sufficient functional and structural information has accumulated in some cases
to allow their rapid development.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Localization and function
Introduction
In this chapter, the term 'deubiquitylating enzyme' (DUB)
is used to describe any enzyme that can hydrolyze a pep-
tide, amide, ester or thiolester bond at the C-terminus of
UBIQ (ubiquitin). DUBs can cleave the linear products of
UBIQ gene translation [1]; the post-translationally
formed branched peptide bonds in mono- or multi-ubiq-
uitylated conjugates [2]; ubiquitylated remnants resulting
from proteasome-mediated degradation [3] and other
small amide or ester adducts [3,4]. DUBs thus have the
potential to regulate any UBIQ-mediated cellular process,
the two best characterized being proteolysis and protein
trafficking/endocytosis.
In mammals there are some 80–90 DUBs categorized into
five gene families: the ubiquitin C-terminal hydrolases
(UCHs); the ubiquitin-specific peptidases (USPs/UBPs);
the ovarian tumor (OTU) domain proteins; the Josephin
or Machado-Joseph disease (MJD) proteins and the JAMM
(Jab1/MPN domain-associated metalloisopeptidase)
domain proteins. The first four families are cysteine pepti-
dases, while the JAMM proteins are zinc metalloisopepti-
dases. These DUB families have been the subjects of recent
reviews [5-7]. Since linear UBIQ fusion proteins are
cleaved very rapidly, perhaps co-translationally [1], it is
unclear which DUB(s) cleave these precursors in vivo to
provide free UBIQ. However, mutating or inhibiting a
DUB(s) that produces free UBIQ would have pleiotropic
effects, in that it would deplete free UBIQ levels and
inhibit all UBIQ-dependent functions non-specifically.
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DUBs that cleave branched UBIQ conjugates presumably
make up the bulk of the 80–90 DUBs, and provide sub-
strate specificity to deubiquitylation. Most DUBs contain
a catalytic domain that has sequence similarity within
subfamilies and structural similarity across subfamilies [5-
8], and unrelated sequences either N-terminal or C-termi-
nal (or both) to the catalytic domain. These flanking
sequences have been shown to mediate substrate binding
in a few cases (see DUBs and disease: UBP7/USP7/HAUSP
and  DUBs and disease: UBP33/USP33/VDU1,
UBP20USP20/VDU2) and presumably serve as substrate
binding domains in all DUBs. These flanking sequences,
along with the catalytic core, could also contribute bind-
ing and cleavage specificity for different UBIQ-UBIQ link-
ages. Some DUBs function at the proteasome to edit and/
or remove UBIQ chains; one example that is linked to dis-
ease is UBP14 (USP14) (see DUBs and disease: UBP14/
USP14).
Since most DUBs have been identified only by means of
sequence similarity to catalytic motifs, there is little
known functional information on many of these
enzymes. However, the relatively few examples where
functional insights have been gained (see DUBs and dis-
ease) indicate that DUBs can play crucial regulatory roles
in the ubiquitin proteasome system (UPS), making them
ideal drug target candidates for therapeutic intervention
in UPS-related diseases.
DUBs and disease
UBP6/USP6/TRE-17/TRE-2
UBP6 (encoded by USP6/TRE-17), the first DUB to be
identified as an oncogene [9,10], has in recent years been
directly linked to human cancers, primarily aneurysmal
bone cysts (ABCs), which are locally aggressive bone
tumors. ABCs were previously regarded as non-neoplastic,
but recent cytogenetic studies have identified clonal rear-
rangements that often feature chromosome 17p13 – the
USP6 or TRE-17 (originally termed TRE-2) locus. There
are five known examples of chromosomal rearrangements
that have positioned USP6 downstream of a heterologous
gene promoter, in turn forcing inappropriate USP6
expression in a bone/mesenchymal context: Osteomodulin;
COL1A1 (Collagen 1A1);  THRAP3 (TRAP150);  CNBP
(ZNF9) and CDH11 [11-13]. High-level UBP6 expression
was also detected in four other human cancers originating
from mesenchymal neoplastic cells in a bone context (one
Ewing's sarcoma, two osteoblastomas and one myofi-
broma), but not in 50 other non-ABC tumors, suggesting
that UBP6 could have a broader oncogenic role in mesen-
chymal tumors [13]. Recent work has also revealed that
the USP6 product regulates actin remodeling and vesicu-
lar trafficking, and could thus regulate cell motility and
invasiveness [14]. In all five cases of UBP6-linked human
cancers referred to above, it remains unclear whether the
heterologous promoters cause overexpression of normal,
full-length UBP6 protein, or whether there have been fur-
ther mutations, deletions, or alternate splicing within
USP6 to produce an altered, oncogenic UBP6 protein.
UBP7/USP7/HAUSP
One well characterized case that illustrates the possible
link between DUBs and disease is the mammalian DUB
UBP7 (encoded by USP7/HAUSP), a 1102 amino acid
member of the USP family. The N-terminal domain of
UBP7 (residues 1–208) contains a TRAF (tumor necrosis
factor receptor-associated factor) domain [15] that binds
to both the P53 (p53) tumor suppressor protein [16,17]
and the MDM2 ubiquitin ligase, which ubiquitylates P53
[18]. The remainder of UBP7 comprises a catalytic core
(residues 208–560) that cleaves UBIQ, and a C-terminal
domain (residues 560–1102) of unknown function. Since
UBP7 can deubiquitylate and stabilize P53 in vitro, it was
suggested that the role of UBP7 was to stabilize P53 in vivo
[16]. More recent work, however, showed that UBP7 can
also deubiquitylate and thus stabilize MDM2 (which aut-
oubiquitylates itself) [19,20]. UBP7 forms a tighter com-
plex with MDM2 than with P53 [21], consistent with
observations that UBP7's primary role could be deubiq-
uitylating and stabilizing MDM2 (and thus increasing
ubiquitylation of P53), rather than deubiquitylating and
stabilizing P53 [20]. MDM2 is not the only P53 ubiquitin
ligase and additional proteins that play a role in P53 ubiq-
uitylation, deubiquitylation and degradation have been
recently reviewed [22]. One further member of this com-
plex interplay was recently identified as the protein DAXX
(death domain-associated protein). DAXX simultane-
ously binds to MDM2 and UBP7, and mediates the stabi-
lizing effect of UBP7 on MDM2 [23]. In response to DNA
damage, DAXX (and UBP7) dissociate from MDM2,
which correlates with MDM2 self-degradation.
Pathogenic mutations within UBP7 itself have not yet
been described. However, a recent study that investigated
UBP7 expression and TP53 gene status in non-small cell
lung carcinomas found that, in 93 of the 131 patients
examined, either mutant P53 or reduced UBP7 expression
was observed [24]. A statistically significant association
between reduced UBP7 levels and reduced P53 protein
expression was observed in tumors with wild-type P53,
while a more dramatic association was seen in tumors
with mutant P53. The authors concluded that the concur-
rent evaluation of both UBP7 expression and P53 gene
status was a significant prognostic indicator in adenocar-
cinoma patients [24]. MDM2 expression was not investi-
gated in this study though it could be another useful
prognostic indicator, given that the protein can regulate
P53 levels.BMC Biochemistry 2008, 9(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/9/S1/S3
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Several disease-causing viruses also target P53 levels by
manipulating the interaction between UBP7 and P53.
These include the HSV protein ICPO (which is a ubiquitin
RING finger ligase that targets several cellular proteins for
degradation, including P53 [25]), and the Epstein-Barr
nuclear antigen 1 (EBNA1) protein, which displaces UBP7
from P53 [26].
In addition to having multiple targets in the same path-
way (i.e. P53, MDM2 and MDM4 [MDMX]), UBP7 has at
least one other non-proteolytic target. The transcription
factor forkhead box O (FOXO) becomes monoubiquit-
ylated in response to increased cellular oxidative stress,
resulting in its re-localization to the nucleus and an
increase in its transcriptional activity. UBP7 removes
UBIQ from monoubiquitylated FOXO, and negatively
regulates FOXO transcriptional activity towards endog-
enous promoters [27]. Thus, we must keep in mind that
DUBs not only regulate protein degradation, but also pro-
tein trafficking/localization.
CYLD
Mutations in the cylindromatosis protein (CYLD), a
tumor suppressor, are linked to familial cylindromatosis
(MIM132700), an autosomal dominant predisposition to
multiple neoplasms of skin appendages [28,29]. The C-
terminal 365 amino acids of the 953-residue CYLD pro-
tein comprise a variant USP-type DUB catalytic core, and
CYLD has been shown to possess deubiquitylating activity
both in vitro and in whole cells. This deubiquitylating
activity was specific to non-Lys48-linked UBIQ chains
[30]. CYLD functions to downregulate NFκB signaling, in
which the UPS has several roles [30]. Upon receptor acti-
vation, TRAF2, TRAF6 and the NEMO (IKKγ) subunit are
polyubiquitylated with Lys63-linked UBIQ chains, which
is a necessary process to activate the IKK complex to phos-
phorylate IκB. IκB in turn becomes polyubiquitylated
with Lys48-linked ubiquitin chains and is degraded,
releasing NFκB for translocation to the nucleus to enable
gene activation [30-32]. CYLD acts to downregulate NFκB
signaling by removing these activating Lys63-linked UBIQ
chains [30]. Reduced or absent CYLD activity allows pro-
longed NFκB signaling, increases resistance to apoptosis
and hence could lead to tumor formation [31]. CYLD is
expressed in a broad range of tissue types, and it remains
unclear as to why CYLD mutations only give rise to skin
tumors [33].
In a study of 25 cylindromatosis families, 21 had CYLD
mutations resulting in truncations or frameshift altera-
tions within the C-terminal two-thirds of the protein that
would abolish its deubiquitylating activity, thus indicat-
ing a correlation between tumorigenesis and reduced deu-
biquitylating activity [33]. Recent studies on CYLD-
deficient mice demonstrated a deficiency in T-cell devel-
opment [34], and observed that activation of their
immune cells led to increased NFκB signaling, a higher
susceptibility to induced colonic inflammation and
increased incidence of tumors when compared with con-
trols in a colitis-associated cancer model [35].
TNAP3/A20/TNFAIP3
Another DUB that plays a role in downregulating NFκB
signaling is TNAP3 (A20, encoded by TNFAIP), which has
an OTU DUB domain. Previous studies of yet another
negative regulator of NFκB signaling, OTU7B (Cezanne),
determined that the N-terminal OTU domain of this pro-
tein conferred its DUB activity [36], which was subse-
quently shown for TNAP3 [37]. TNA3P can cleave both
Lys48- and Lys63-linked UBIQ chains in vitro, but in vivo
appears to have specificity for Lys63 chains. However,
TNAP3 also possesses a novel zinc finger-type ubiquitin
ligase (E3) domain, which can assemble Lys48-linked
UBIQ chains in vitro and in transfected cells [37]. Thus,
TNAP3 acts as an inhibitor of NFκB signaling by removing
the (activating) Lys63 chains on the tumor necrosis factor
(TNF) receptor-interacting protein RIP, and then assem-
bling Lys48 linked chains on RIP by virtue of its ubiquitin
ligase domain. This results in the degradation of RIP, thus
preventing its activation of NFκB via the TNF-mediated
pathway [37].
To date, no TNAP3 mutations have been linked to human
disease. However, TNAP3-deficient mice develop severe
inflammation and cachexia, are hypersensitive to both
lipopolysaccharide and TNF, and die prematurely, con-
sistent with failure to terminate TNF-induced NFκB
responses [38]. The role of the UBIQ pathway in NFκB sig-
naling has been extensively reviewed [39-41].
UBP33/USP33/VDU1, UBP20/USP20/VDU2 and von Hippel-Lindau 
disease
Von Hippel-Lindau disease is an autosomal dominant
disorder that predisposes affected individuals to a variety
of tumors, including hemangioblastomas in the CNS and
retina, clear cell carcinomas of the kidney, pheochromo-
cytomas of the adrenal gland, and pancreatic cysts, adeno-
mas and islet cell tumors (reviewed in [42]). UBP33
(encoded by USP33/VDU1) and UBP20 (encoded by
USP20/VDU2) are 59% identical USP-type DUBs that
interact with the tumor suppressor E3 ubiquitin ligase
VHL (pVHL), mutations in which are associated with von
Hippel-Lindau disease [43]. UBP33 and UBP20 interact
with the β-domain of VHL, leading to their ubiquitylation
and degradation by the proteasome [44]. The β-domain of
VHL is the region of the protein that harbors the naturally
occurring mutations found in von Hippel-Lindau disease.
Some of these mutations have been shown to disrupt
UBP33/20 interaction with VHL, suggesting an important
role for UBP33/20 in this disease [43,44]. One target ofBMC Biochemistry 2008, 9(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/9/S1/S3
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VHL is the α-subunit of the transcription factor hypoxia-
inducible factor-1 (HIF-1) [45], which regulates the genes
involved in angiogenesis, glucose metabolism, cell prolif-
eration, invasion and metastasis [46]. The inability to
degrade HIF1A (HIF-1α) leads to overexpression of HIFA
target genes and to a variety of tumors [42]. Recently, it
has been shown that UBP20, but not UBP33, interacts
with HIFIA and can specifically deubiquitylate and stabi-
lize it, antagonizing VHL-mediated ubiquitylation of the
transcription factor [45]. This UBP20/HIF1A/VHL inter-
play is functionally similar to the UBP7/P53/MDM2 situ-
ation described previously (see DUBs and disease: UBP7/
USP7/HAUSP).
UBP14
UBP14 (encoded by ubp14/gid6) is a USP-type DUB that is
localized to the proteasome by virtue of a ubiquitin-like
domain N-terminal to its catalytic core. This DUB has
been best studied in yeast, where it was found that UBP14
activity was increased 300-fold upon binding to the pro-
teasome, and it was originally proposed to assist in the
release of UBIQ from proteasome-bound multi-ubiquit-
ylated conjugates [47]. In yeast, loss of UBP14 depletes
free cellular UBIQ levels due to increased degradation of
UBIQ by the proteasome, and renders cells susceptible to
stresses that impose extra load on UBIQ-dependent prote-
olysis [47]. However, more recent studies suggest that
UBP14 regulates proteasome activity by actually delaying
UBIQ chain removal, and that it is involved in a dynamic
remodeling of UBIQ chains at the proteasome in conjunc-
tion with a proteasome-bound ubiquitin ligase, HUL5
[48,49]. In mammals, UBP14 (encoded by USP14) is also
associated with the proteasome, and loss of UBP14 in
mice also leads to depletion of UBIQ [50], resulting in an
ataxia phenotype due to defects in synaptic transmission
[51]. However, it is not yet clear whether this is due to a
general defect in proteolysis (by analogy to the yeast
ubp14  deletion mutant) or to a more specific, perhaps
non-proteasomal role for UBP14 in neurons.
UCHL1
Ubiquitin C-terminal hydrolase isozyme L1 (UCHL1) cat-
alyzes the hydrolysis of C-terminal ubiquityl esters and
amides, releasing UBIQ from substrates [4]. UCHL1 is a
highly abundant neuronal enzyme, comprising up to 2%
of total brain protein [52]. Although it has mainly been
implicated in deubiquitylation, it has also been shown in
vitro to have ubiquitin ligase activity and this activity has
been correlated with dimerization of the enzyme. Muta-
tions in the UCHL1 gene have been linked to susceptibil-
ity to and protection from Parkinson's disease (PD)
[53,54]. UCHL1 was initially linked to PD in a German
family [55] where a point mutation at nucleotide C277G
led to the amino acid substitution Ile93Met [56,57]. The
Met93 variant has a severely diminished hydrolase activity
and a lower E3 ligase activity compared with wild-type
UCHL1. UCHL1 is found in Lewy body protein aggregates
associated with PD. These Lewy bodies amass a range of
normal and abnormal proteins, many of which are ubiq-
uitylated [58]. However, this polymorphism has only
been observed in one PD family. The second polymor-
phism in UCHL1 results in an amino acid change,
Ser18Tyr [59]. This mutation is, however, protective
against PD [60] and delays the age of onset of disease. The
Tyr18 allele prevents the formation of UCHL1 dimers and
therefore lacks ubiquitin ligase activity. In addition, the
Tyr18 allele has been shown to increase the hydrolase
activity of UCHL1 in vitro [61,62]. Taken together, these
results suggest that increased UCHL1 hydrolase activity is
protective against PD, but that the specific substrates of
UCHL1 require further investigation.
ATX3
Spinocerebellar ataxia (SCA) type-3 or Machado-Joseph
disease (MJD) is a member of the CAG/polyglutamine
repeats disease family [63,64]. Expanded polyglutamine
confers a toxic gain of function on the disease protein,
presumably through an increased propensity towards
aggregation, altered protein expression or both [65]. ATX3
(Ataxin-3), the disease protein associated with SCA3/
MJD, is a ubiquitously expressed protein and a member of
a novel family of DUBs defined by the Josephin or MJD
domain [66-68]. Normally, the protein contains 12–40
glutamines near its C-terminus, whereas in disease the
polyglutamine domain expands to ~55–84 glutamines.
Expression of mutant ATX3 is widespread, although the
neurodegeneration in MJD has been described only in
particular regions of the brain such as the cerebellum, sub-
stantia nigra and pontine nuclei. It has been proposed
that the cellular expression of the disease gene is not in
itself sufficient to cause neuronal degeneration, and that
other cell-specific factors must be invoked to explain the
restricted neuropathology seen in MJD [63].
DUBs linked to other diseases
There are also numerous examples of other DUBs linked
to different diseases that have not been covered herein,
owing to space constraints. These include (but are not lim-
ited to): UBP1 (encoded by USP1), which deubiquitylates
a component of the Fanconi anemia DNA repair complex
[69]; BAP1, a UCH-type DUB that binds to the BRCA1
breast-cancer susceptibility protein [70]; UBP11 (encoded
by USP11), which binds to BRCA2 [71]; UBP4 (encoded
by USP4), an oncoprotein linked to lung cancer [72] that
interacts with the Retinoblastoma tumor suppressor pro-
teins [73,74], and also interacts with and deubiquitylates
the ubiquitin ligase RO52 [75], an autoantigen associated
with the autoimmune disease Sjögren's syndrome [76];
the DUB-1 and DUB-2 family of cytokine-inducible USP-
type DUBs, where DUB-2 deubiquitylates the commonBMC Biochemistry 2008, 9(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/9/S1/S3
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cytokine receptor subunit gamma(c) [77]; and the UBP2a
splice variant of UBP2 (encoded by USP2), which regu-
lates the stability of fatty acid synthase in prostate cancer,
protects cells from apoptosis and interacts with MDM2
[78,79]. Also, while this review has focused on mamma-
lian DUBs, there are also relevant examples from other
species, such as the Drosophila DUB fat facets (FAF) and its
substrate, the epsin ortholog liquid facets (LQF) [80,81],
which play a clear role in endocytosis and Notch signal-
ing, with implications for human disease.
Disease, mutation, expression, knockout
Earlier biochemical assays of DUBs employed small ubiq-
uitin (UBIQ)-ester adducts [3,4] and these were followed
by gel-based or enzymatic assays based on larger UBIQ
protein fusions [6]. More recently, a UBIQ-fluorescent
leaving group substrate has been widely used [82,83].
UBIQ chains of defined lysine linkage have also been
developed, mainly through the pioneering work of Cecile
Pickart (Johns Hopkins University, Baltimore, USA) [84],
and these are useful in determining DUB preference for
chain topology.
Recently, RNAi-based knockdown of a large number of
DUBs has been successfully employed in cell-based
screens aimed at identifying roles for DUBs in regulatory
pathways, such as CYLD in NFκB signaling [31] and UBP1
(encoded by USP1) in Fanconi anemia [69]. More
recently, mice lacking specific DUBs have been developed,
and these will provide useful models for further under-
standing the roles of DUBs in disease. For example, the
CYLD- [34,35] and TNAP (A20)- [38] deficient mice pro-
vide useful models to address the role of these DUBs in
inflammatory disease. Similarly, the UBP7 (USP7)-null
mouse, which shows increased P53 (p53) levels [20], led
investigators to conclude that UBP7's main substrate
could be the MDM2 ubiquitin ligase, rather than P53
itself.
In two other cases, mutations in naturally occurring
mouse disease models were mapped to DUB genes. The
Ataxia mouse, bred for some 50 years by (and available
from) the Jackson Laboratories, was found in 2002 to har-
bor an inactivating insertion in the proteasome-associated
DUB UBP14 [51]. While it is clear that the null mutant has
a neurological phenotype, it remains unclear whether this
is a non-specific (proteasomal) or specific substrate effect.
However, the availability of the Usp14  mutant mouse
should accelerate discovery in this area.
Secondly, the mutation in the gracile axonal dystrophy
(gad) mouse was mapped to a deletion in the Uchl1 gene
[85], and subsequent work on this model revealed that
UCHL1 regulates the morphology and differentiation of
neural progenitor cells [86]. Thus the Uchl1 (gad) mouse
provides a useful model for further study.
One other mouse model, the Usp18-null mouse, is useful
in the study of interferon signaling and innate immunity
against viral and bacterial infection [87]. However, it has
not been covered in detail here, because UBP18 cleaves
the interferon-stimulated ubiquitin-like protein UCRP
(ISG15), rather than UBIQ itself.
Disease targets and ligands
DUBs represent the newest, and least studied, family of
enzymes in the ubiquitin proteasome pathway. Poten-
tially, they have the ability to regulate the ubiquitylation
status, and thus function, localization, and/or degrada-
tion, of any ubiquitylated protein, and therefore should
be ideal drug targets for therapeutic intervention. How-
ever, there are no specific drugs reported for any DUB to
date. Theoretically, there should be two possible routes of
intervention: (i) modulation of the DUB's enzymatic
activity, or (ii) modulation of the DUB's interaction with
its ubiquitylated substrate and/or with the cognate ligase.
There are several non-specific inhibitors of whole classes
of DUBs, such as ubiquitin-aldehyde [80], which blocks at
least the UCH and USP families, as well as other cysteine
protease inhibitors. However, these target the catalytic
protease domains of DUBs, and would at best have broad
specificity. Other screens using branched peptide mimics
of UBIQ-UBIQ linkages have also been performed (e.g.
[88]); these may allow development of inhibitors of cleav-
age of specific lysine linkages. Further approaches aim to
identify candidate inhibitors of deubiquitylating activity
based on the X-ray crystallographic structure of DUB
active sites (World Patent WO9901567). It could also be
possible to stimulate DUB activity with small molecules
that may enhance active site configuration, or that induce
DUB gene expression, although such approaches have not
been reported.
Given that the interacting regions between DUBs and
their substrates (or cognate ubiquitin ligases) are now
being defined, it is hoped that more rapid progress
towards specific drugs will be made. For example, given
the apparent primary role of UBP7 (USP7) in regulating
MDM2 levels, and the well-defined binding sites of these
proteins [21], UBP7 would be a logical choice for thera-
peutic intervention. Preventing UBP7-MDM2 interaction
would destabilize MDM2, and thus stabilize P53 (p53)
(see DUBs and disease: UBP7/USP7/HAUSP). This should
have application in any disease where P53 is wild-type,
and where stabilizing it would restore normal P53 check-
point function. Such possibilities have been theoretically
explored as a therapeutic approach to modulate P53 levels
in hematopoietic tumors (where P53 is rarely mutated
and thus amenable to manipulation [89]), but as yet, noBMC Biochemistry 2008, 9(Suppl 1):S3 http://www.biomedcentral.com/1471-2091/9/S1/S3
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UBP7-targeted drugs have been described. Similarly, once
the full in vivo ramifications of the UBP20 (USP20)/HIF1A
(HIF-1κ/VHL (pVHL) interplay are understood (see DUBs
and disease: UBP33/USP33/VDU1, UBP20/USP20/VDU2
and von Hippel-Lindau disease), modulation of these pro-
tein-protein interactions should allow regulation of
HIF1A levels in von Hippel-Lindaudisease.
New frontiers in drug discovery
The most important issue to be addressed for most DUBs
is to define the proteins that they interact with and deu-
biquitylate, be they (i) ubiquitylated proteins destined for
degradation, trafficking, or some other consequence, or
(ii) ubiquitin ligases, as it is becoming apparent that many
DUBs interact with, and stabilize, ligases
[19,21,44,75,79]. For the large majority of DUBs, physio-
logical substrates remain unidentified, though it is clear
from the examples discussed in this review that many
DUBs have clear links to disease. This remains a major
barrier to drug development. Current efforts, such as the
DUB family-wide RNAi knockdown screens (e.g. [31,69]),
should identify pathways that DUBs regulate, thus allow-
ing focused efforts on substrate identification.
Once these interactions have been defined at the molecu-
lar and structural level, they can be exploited as drug tar-
gets. The P53 (p53)/MDM2/UBP7 (USP7) example gives
a clear indication that we need to understand all aspects
of a DUB's role before drugs can be rationally designed.
One major unresolved question concerns the numbers of
ubiquitin ligases (perhaps 500) compared with the
number of DUBs (some 80–90). Does the fewer number
of DUBs mean that some substrates do not have a protec-
tive DUB, and/or that DUBs are more promiscuous than
ligases and can deubiquitylate several substrates, and/or
that some ligases do not have a protective DUB? We need
to understand the complex interplay between ubiquitin
ligases, DUBs and substrates, and whether the DUB's role
is to promote degradation, inhibit degradation, or is non-
proteolytic, before pharmacological intervention is
explored.
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